KYNTRA BIO, INC.

Listed Company

KYNBCIK 0000921299NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$6.44M

Net Income

$183.45M

Total Assets

$119.59M

Equity

$-30.04M

Shares Out

4.05M

Op. Cash Flow

$-4.77M

Business

FIBROGEN INC is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia. It is developing FG-3246, a CD46-targeting antibody‑drug conjugate, and associated PET imaging agent FG-3180, and has co‑developed the oral HIF‑PH inhibitor roxadustat (EVRENZO) for anemia. Its operations are organized around oncology drug and diagnostic development and anemia drug development and commercialization, supported by collaboration, licensing and manufacturing arrangements. FibroGen sells and licenses products through partners and third‑party manufacturers across markets including China, Europe, Japan, the U.S., Canada, Mexico and other global territories.

Summary from filing dated 2025-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	6	30	47	141	235
Cost of goods sold	556,000	16	4	20	13
Research and development	24	96	266	297	387
Selling, general and administrative	28	49	86	125	124
Restructuring charge	553,000	20	13	0	0
Total operating costs and expenses	52	180	370	442	524
Loss from operations	−46	−150	−323	−301	−289
Interest expense	−9	−8	−8	−1	−1
Loss on debt extinguishments	−7	0	—	—	—
Interest income and other income (expenses), net	3	5	8	8	−1
Total interest and other, net	−12	−3	−501,000	6	−2
Loss from continuing operations before income taxes	−58	−153	−323	−295	−291
Benefit from income taxes	−90,000	−269,000	−252,000	358,000	347,000
Loss from continuing operations	−58	−153	−323	—	—
Income from discontinued operations, net of tax	242	106	39	—	—
Net income (loss)	183	−48	−284	−294	−290
Loss from continuing operations per share - basic	−14.4	−38.26	−3.32	—	—
Loss from continuing operations per share - diluted	−14.4	−38.26	−3.32	—	—
Income from discontinued operations per share - basic	59.77	26.37	0.4	—	—
Income from discontinued operations per share - diluted	59.77	26.37	0.4	—	—
Net income (loss) per share - basic	45.37	−11.89	−2.92	−3.14	−3.14
Net income (loss) per share - diluted	45.37	−11.89	−2.92	−3.14	−3.14
Basic	4	4	97	94	92
Diluted	4	4	97	94	92

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	48	50	82	156	171
Short-term investments	41	0	122	266	234
Accounts receivable, net	216,000	481,000	5	16	17
Inventories	4	3	17	40	31
Prepaid expenses and other current assets	6	32	40	14	20
Current assets held for sale	0	111	66	—	—
Total current assets	99	197	332	493	474
Long-term investments	20	0	—	—	—
Other assets	361,000	1	3	5	7
Long-term assets held for sale	0	17	18	—	—
Total assets	120	215	424	610	774
Accounts payable	4	5	16	31	26
Accrued and other current liabilities	20	62	133	220	173
Deferred revenue	5	27	13	13	16
Current liabilities held for sale	0	39	44	—	—
Total current liabilities	29	133	218	274	225
Product development obligations	20	17	18	17	18
Deferred revenue, net of current	255,000	115	158	186	187
Senior secured term loan facilities, non-current	0	73	72	0	—
Liability related to sale of future revenues, non-current	66	59	51	49	—
Other long-term liabilities	82,000	822,000	3	6	26
Long-term liabilities held for sale	0	356,000	2	—	—
Total liabilities	115	398	586	612	545
Commitments and Contingencies (Note 11)	—	—	—	—	—
Redeemable non-controlling interests	21	21	21	0	—
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2025 and 2024; 4,047 and 4,037 shares issued and outstanding at December 31, 2025 and 2024	1	1	988,000	942,000	929,000
Additional paid-in capital	1,677	1,669	1,644	1,541	1,476
Accumulated other comprehensive loss	−2	−6	−7	−6	−4
Accumulated deficit	−1,706	−1,889	−1,842	−1,558	−1,264
Total stockholders' deficit attributable to Kyntra Bio	−30	−226	−204	−21	209
Nonredeemable non-controlling interests	13	20	20	20	—
Total deficit	−17	−205	−184	−1	229
Total liabilities, redeemable non-controlling interests and deficit	120	215	424	610	774

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	183	−48	−284	−294	−290
Depreciation	713,000	3	10	10	10
Amortization of finance lease right-of-use assets	35,000	38,000	412,000	587,000	5
Net accretion of premium and discount on investments	−72,000	−2	−5	2	2
Investment income in unconsolidated variable interest entity	−2	−4	−3	−2	−1
Gain on divestiture	−53	0	—	—	—
Impairment of property and equipment	2	0	—	—	—
Loss on disposal of property and equipment	0	3	4,000	−1,000	233,000
Stock-based compensation	7	25	51	66	71
Dividend received from unconsolidated variable interest entity	4	2	2	0	0
Accounts receivable, net	−3	−7	3	765,000	25
Inventories	5	22	−2	−11	−14
Prepaid expenses and other current assets	54	−16	−28	5	−10
Operating lease right-of-use assets	808,000	66	12	11	4
Other assets	−902,000	1	256,000	263,000	−4
Accounts payable	−28	15	−16	6	805,000
Accrued and other liabilities	−53	−94	−50	91	16
Operating lease liabilities, current	−568,000	−13	4	−547,000	503,000
Deferred revenues	−136	−28	−28	−4	58
Accrued interest expense related to sale of future revenues	8	2	0	—	—
Accrued interest for finance lease liabilities	6,000	14,000	−11,000	33,000	−75,000
Operating lease liabilities, non-current	−202,000	−66	−13	−9	−4
Other long-term liabilities	495,000	−540,000	−3	−18	−12
Net cash used in operating activities	−5	−138	−315	−146	−82
Purchases of property and equipment	−38,000	−266,000	−3	−4	−5
Proceeds from divestiture, net of cash transferred	97	0	—	—	—
Proceeds from sale of property and equipment	0	1	0	6,000	0
Purchases of available-for-sale securities	−61	−9	−252	−164	−484
Proceeds from maturities of investments	0	134	401	284	83
Net cash provided by investing activities	35	126	154	89	−427
Repayments of senior secured term loan facilities	−75	0	—	—	—
Payment of senior secured term loan facilities pay-off premium and fees	−6	0	—	—	—
Repayments of finance lease liabilities	−10,000	−40,000	−148,000	−135,000	−5
Cash paid for payroll taxes on restricted stock unit releases	−69,000	−354,000	−237,000	−5	−7
Cash paid to non-controlling interest	−5	0	—	—	—
Payment of issuance cost under ATM Program	−46,000	0	—	—	—
Proceeds from issuance of common stock under employee stock plans	0	139,000	4	4	13
Net cash used in financing activities	−86	−255,000	123	47	−563,000
Effect of exchange rate change on cash and cash equivalents	1	751,000	−3	−5	3
Net decrease in cash and cash equivalents	−54	−12	−42	−16	−507
Holdback consideration receivable related to divestiture in prepaid expenses and other current assets	4	—	—	—	—
Interest payments	8	16	6	104,000	94,000
Cash and cash equivalents of continuing operations	48	50	82	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro